PHI 501
Alternative Names: PHI-501Latest Information Update: 22 Jun 2024
At a glance
- Originator Pharos I&BT
- Developer Pharos iBio
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA repair enzyme inhibitors; NRAS protein inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Malignant melanoma
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Malignant melanoma were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharos iBio plans a phase clinical trial for Malignant melanoma (Second-line therapy or greater)
- 26 Feb 2024 Pharmacodynamics data from preclinical trial in Colorectal cancer were presented at the ESMO Targeted Anticancer Therapies Congress 2024